The	O
antiangiogenic	O
agent	O
linomide	O
inhibits	O
the	O
growth	O
rate	O
of	O
von	B-Cancer
Hippel	I-Cancer
-	I-Cancer
Lindau	I-Cancer
paraganglioma	I-Cancer
xenografts	I-Cancer
to	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
the	O
potential	O
usefulness	O
of	O
the	O
antiangiogenic	O
compound	O
linomide	O
for	O
treatment	O
of	O
von	B-Cancer
Hippel	I-Cancer
-	I-Cancer
Lindau	I-Cancer
(	I-Cancer
VHL	I-Cancer
)	I-Cancer
-	I-Cancer
related	I-Cancer
tumors	I-Cancer
.	O

Paraganglioma	B-Tissue
tissue	I-Tissue
fragments	I-Tissue
obtained	O
at	O
surgery	O
from	O
a	O
VHL	O
type	O
2a	O
patient	O
were	O
transplanted	O
s	O
.	O
c	O
.	O
to	O
male	O
BALB	O
/	O
c	O
nu	O
/	O
nu	O
(	O
nude	O
)	O
mice	O
:	O
(	O
a	O
)	O
2	O
-	O
3	O
-	O
mm	O
fragments	B-Tissue
for	O
"	O
prevention	O
"	O
experiments	O
;	O
and	O
(	O
b	O
)	O
2	O
-	O
3	O
-	O
mm	O
fragments	B-Tissue
allowed	O
to	O
grow	O
to	O
1	O
cm	O
for	O
"	O
intervention	O
"	O
studies	O
.	O

Both	O
groups	O
received	O
either	O
0	O
.	O
5	O
mg	O
/	O
ml	O
linomide	O
in	O
drinking	O
water	O
or	O
acidified	O
water	O
and	O
were	O
followed	O
until	O
tumor	B-Cancer
diameter	O
reached	O
3	O
cm	O
or	O
for	O
4	O
weeks	O
.	O

In	O
both	O
the	O
prevention	O
and	O
intervention	O
experiments	O
,	O
a	O
significant	O
diminution	O
of	O
tumor	B-Cancer
size	O
and	O
weight	O
was	O
observed	O
in	O
the	O
drug	O
-	O
treated	O
animals	O
.	O

In	O
vivo	O
nuclear	O
magnetic	O
resonance	O
analysis	O
of	O
tumor	B-Cancer
blood	B-Organism_substance
flow	O
in	O
linomide	O
-	O
treated	O
animals	O
showed	O
localization	O
of	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
almost	O
exclusively	O
to	O
the	O
periphery	O
of	O
the	O
poorly	O
vascularized	O
tumors	B-Cancer
with	O
a	O
significant	O
reduction	O
of	O
both	O
vascular	B-Multi-tissue_structure
functionality	O
and	O
vasodilation	O
.	O

Histological	O
examination	O
of	O
tumors	B-Cancer
from	O
linomide	O
-	O
treated	O
animals	O
revealed	O
marked	O
avascularity	O
.	O

Treated	O
animals	O
also	O
displayed	O
a	O
2	O
.	O
4	O
-	O
fold	O
reduction	O
of	O
tumor	B-Cancer
vascular	O
endothelial	O
growth	O
factor	O
mRNA	O
levels	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
in	O
VHL	O
disease	O
,	O
therapy	O
directed	O
at	O
inhibition	O
of	O
constitutively	O
expressed	O
VEGF	O
induction	O
of	O
angiogenesis	O
by	O
VHL	B-Cancer
tumors	I-Cancer
may	O
constitute	O
an	O
effective	O
medical	O
treatment	O
.	O

